住院患者使用利奈唑胺致贫血的相关危险因素

Risk factors associated with anemia in patients who received linezolid therapy

目的:探讨住院患者使用利奈唑胺(LZD)治疗期间发生贫血不良反应的相关危险因素。方法:采用回顾性研究,收集2012年5月至2017年5月温州医科大学附属第一医院接受LZD治疗且监测血药浓度的161例住院患者的临床资料,采用logistic回归分析LZD诱发贫血不良反应的相关危险因素。结果:31例(占19.2%)患者被评估为LZD相关性贫血,LZD治疗期间,中重度肾功能不全患者[GFR<60 mL·(min·1.73 m^2)^-1](OR=3.47,95%CI:1.49~8.13,P=0.004)以及药物谷浓度≥7 mg·L-1(OR=2.87,95%CI:1.11~6.93,P=0.024)者发生相关性贫血风险更高。结论:LZD相关性贫血与肾功能及体内药物浓度密切相关。

Objective:To investigate the factors affecting linezolid-induced anemia in hospitalized patients.Methods:A retrospective study was performed to collect data in 161 adult inpatients who received linezolid between May 2012 to May 2017.The risk factors of linezolid-related anemia were confirmed by univariate and multivariate logistic regression.Results:Of all the patients enrolled,linezolid-induced anemia developed in 31(19.2%)patients during therapy.The incidence of anemia occurred more frequently in patients who received linezolid at concentration≥7 mg·L-1(OR=2.87,95%CI:1.11-6.93,P=0.024)and those with moderate-severe renal impairment[GFR<60 mL·(min·1.73 m2)-1](OR=3.47,95%CI:1.49-8.13,P=0.004).Conclusion:The results of our study indicated that high plasma linezolid concentration and renal impairment significantly affected the development of linezolid-induced anemia.